Drugs / NARATUXIMAB EMTANSINE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01534715 | Jan 2012 → Jul 2016 | chronic lymphocytic leukemia/small lymphocytic lymphoma | ImmunoGen, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02564744 | Jun 2016 → Jan 2021 | diffuse large B-cell lymphoma | Debiopharm International SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2021-06-14 | Debiopharm International SA | Results Debiopharm’s CD37 antibody drug conjugate shows promising phase II results for the treatment of B-cell malignancies debiopharm.com ↗
Naratuximab emtansine as a late breaking abstract (LB1903) demonstrated that the naratuximab emtansine/rituximab combination could represent a new treatment approach, particularly for heavily pre-treated relapsed/refractory (R/R) DLBCL patients |
| 2015-12-01 | AbbVie | Results ImmunoGen, Inc. Announces Data Presentations at Upcoming 57th ASH Annual Meeting and Exposition abbvie.com ↗
In preclinical assessments, IMGN529 demonstrates marked synergy with rituximab - a widely used therapy for non-Hodgkin lymphoma - which informed our decision to assess this combination clinically. |
| 2015-06-17 | AbbVie | Results ImmunoGen's IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma abbvie.com ↗
Among the findings being presented are: IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, including both GCB and ABC diffuse large B-cell lymphoma (DLBCL); |
| 2014-12-06 | AbbVie | Results ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition abbvie.com ↗
IMGN529 achieved objective responses in four of ten (40%) evaluable patients with heavily pretreated diffuse large B-cell lymphoma (DLBCL) - including a complete response - at the dose levels evaluated to date. |
| 2014-05-14 | AbbVie | Results ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO abbvie.com ↗
Abstracts made public today provide insight on biological effects seen at low doses with IMGN529 and on observed activity threshold for IMGN853. |
| 2011-09-22 | AbbVie | Regulatory ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma abbvie.com ↗
today announced its submission of the Investigational New Drug (IND) application for its IMGN529 product candidate to the U.S. Food and Drug Administration (FDA). |
| 2011-04-04 | AbbVie | Results ImmunoGen, Inc. Announces First Data for Its IMGN529 Product Candidate for Non-Hodgkin's Lymphoma abbvie.com ↗
This product candidate has demonstrated highly encouraging activity in preclinical testing and is on track for IND submission this summer. |
All press releases naming this drug 8 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NARATUXIMAB EMTANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109268 ↗ |
| Known as | Debio 1562 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02564744 ↗ |
| Known as | IMGN529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01534715 ↗ |
| Known as | K7153a-smcc-dm1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109268 ↗ |
| Known as | Naratuximab emtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109268 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT01534715 ↗ |
| Target | CD37 | “Leukocyte antigen CD37 binding agent” CHEMBL2109268 ↗ |